Lonza Singapore Receives GMP Certification

The GMP certification from the Singapore Health Science Authority allows Lonza to contract manufacture products for use in the United States and Europe.

AsianScientist (Apr. 25, 2014) – Lonza Bioscience Singapore Pte Ltd has received Good Manufacturing Practice (GMP) certification from the Singapore Health Sciences Authority (HSA).

The audit/conformity assessment, performed by the HSA, confirmed that Lonza Singapore has maintained an overall acceptable level of compliance with the Pharmaceutical Inspection Convention/Co-Operation Scheme (PIC/S) Guide to Good Manufacturing Practice (GMP) for Medicinal Products (Part I) relating to finished products.

PIC/S guidelines to GMP for Medicinal Products (Part I) require that the company is compliant with the standards required for the following: quality management, personnel, premises and equipment, documentation, production, quality control, contract manufacturing and analysis, complaints and product recall, and self-inspection.

“We are proud to be one of the first cell therapy contract manufacturers in Singapore to have received this certification,” said Michael Cicio, Vice President of Operations. “This certification will allow Lonza to contract manufacture investigational medicinal products for aseptically prepared cell-therapy products and will facilitate the use of these products in both the United States and Europe.”

———

Source: Lonza; Photo: epSos.de/Flickr/CC.

Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist